

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 11	ATTY. DOCKET NO. GSL01/C	SERIAL NO. 10/652,814
	APPLICANT Unger, et al.	
	FILING DATE August 29, 2003	GROUP 1633

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	11/622,359	01/11/2007	Unger			
	AB	2002/0142045	10/03/2002	Kurari			
	AC	2006/0018826	01/26/2006	Unger			
	AD	2007/0098713	5/3/2007	Unger			
	AE	4,177,177	12/4/1979	Vanderhoff			
	AF	4,273,875	06/16/1981	Manis			
	AG	4,304,863	12/08/1981	Collins			
	AH	4,332,901	06/01/1982	Goldstein			
	AI	4,336,336	06/22/1982	Silhavy			
	AJ	4,349,629	09/14/1982	Carey			
	AK	4,356,270	10/26/1982	Itakura			
	AL	4,362,867	12/07/1982	Paddock			
	AM	4,363,877	1/21/1982	Goodman			
	AN	4,403,036	09/06/1983	Hartley			
	AO	4,419,450	12/06/1983	Dean			
	AP	5,013,830	05/07/1991	Ohtsuka			
	AQ	5,128,326	07/07/1992	Balazs			
	AR	5,142,047	08/25/1992	Summerton			

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB- CLS	TRANS ?
	AS	WO 00/72679	02/07/2000	PCT			
	AT	WO 01/45764	06/28/2001	PCT			
	AU	WO 01/64164	09/07/2001	PCT			
	AV	WO 01/82964	11/08/2001	PCT			
	AW	WO 01/89579	11/29/2001	PCT			
	AX	WO 01/91808	06/12/2001	PCT			
	AY	WO 02/09735	02/07/2002	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AZ	ABRA (1981) Biochem. Biophys. Acta 666:493-503, "Liposome disposition in vivo: dose and vesicle-size effects"
AAA	ACHARYA (1995) Computerized Medical Imaging and Graphics 19(1):3-25, "Biomedical imaging: a tutorial"
ABB	AHMAD (2005) Anti-Cancer Drugs 16(10):1037-1043 "Targeting CK2 for cancer therapy"
AAA	AIMED (2002) Trend Cell Biol 12(5):226-30, "Joining the cell survival squad: an emerging role for Protein Kinase CK2"
AAB	AKERMAN (2002) PNAS 99(20):12617-12621, "Nanocrystal imaging in vivo"
EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 2 of 11	ATTY. DOCKET NO. GSI.01/C	SERIAL NO. 10/652,814
	APPLICANT Unger, et al.	
	FILING DATE August 29, 2003	GROUP 1633

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	BA	5,185,444	02/09/1993	Summerlin			
	BR	5,188,816	02/23/1993	Sherry			
	BC	5,219,553	06/15/1993	Kraft			
	BD	5,284,646	02/08/1993	Menz			
	BE	5,358,704	10/25/1994	Desreux			
	BF	5,387,124	05/14/2002	Buscemi			
	BG	5,516,507	05/14/1996	N'Guyen			
	BH	5,554,386	09/10/2000	Groman			
	BI	5,580,960	12/03/1996	Burgeson			
	BJ	5,589,466	12/31/1996	Feigner			
	BK	5,593,974	01/14/1997	Rosenberg			
	BL	5,610,031	03/11/1997	Burgeson			
	BM	5,625,040	04/29/1997	Margolis			
	BN	5,626,877	05/06/1997	Amsden			
	BO	5,646,248	07/08/1997	Sawada			
	BP	5,648,465	7/15/1997	Margolis			
	BQ	5,679,323	10/21/1997	Menz			

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	BR	WO 02/100343	12/19/2002	PCT			
	BS	WO 03/087021	10/23/2003	PCT			
	BT	WO 03/087323	10/23/2003	PCT			
	BU	WO 03/087389	10/23/2003	PCT			
	BV	WO 98/08379	03/05/1998	PCT			

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	BW	ALBERT (1998) Exp. Med. 188:1359-68, "Immature dendritic cells phagocytose apoptotic cells via avb5 and CD36, and cross-present antigens to cytotoxic T lymphocytes"
	BX	ALLPORT (2001) Experimental Hematology 1237-1246, "In vivo imaging of gene and cell therapies"
	BY	ANTISENSE RESEARCH AND APPLICATION (1988) Editor: Stanley T. Crooke, Springer-Verlag, pages 1-101
	BRA	AUKHIL (1993) J Biol. Chem. 268(4):2542-2553, "Cell- and heparin-binding domains of the hexabrachion are identified by tenascin expression proteins"
	BBB	BELLO (2001) Cancer Research 61:8730-36, "Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase 2"
	BBC	BENNETT (2003) Heart 89:218-224, "In-stent stenosis: pathology and implications for the development of drug-eluting stents"
	BBB	BRAUN (1997) Pharm. Res. 14(10):1472-78, "Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN- α) in normal and transgenic mice"
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 8 of 11	ATTY. DOCKET NO. GSI01/C	SERIAL NO. 10652,814
	APPLICANT Unger, et al.	
	FILING DATE August 29, 2003	GROUP 1633

U.S. PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS
	HA	6,797,685	9/28/2004	Zhu et al.		

FOREIGN PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS
	HB					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	HC	LACKEY (2002) Bioconjugate Chem. 13, 996-1001, "A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex"				
	HD	LAFLEUR (1997) J. Biol. Chem. 272(52):32798-32803, "Aortic smooth muscle cells interact with tenascin-C through its fibronectin-like domain"				
	HE	LAKKARAJU (2001) J. Biol. Chem. 276(34):32000-007, "Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes"				
	HF	LARREGINA (1997), Immunol. 91:303-13, "Pattern of cytokine receptors expressed by human dendritic cells migrated from dermal explants"				
	HG	LEBEDEVA (2000) European J. of Pharmaceutics and Biopharmaceutics 50:101-119 "Cellular delivery of antisense oligonucleotides"				
	HH	LEE Chl. Rev. Ther. Drug Carr. Sys., (1997) 14:2 173-206, "Lipidic vector systems for gene transfer"				
	HI	LIPSCOMB (2002), Physiol. Rev. 82:97-130, "Dendritic cells: immune regulators in health and disease"				
	HJ	LIU (2003), J Int. Med 253:402-410, "DNA vaccines: a review"				
	HK	LIVANT (2000), Can Resch, 60:309-320, "Anti-sense, antitumorogenic, and Antimetastatic Activities of the PHSCN Sequence in Prostate Carcinoma"				
	HL	MANOME (1998) Immunol. 98:481-490, "Simple chemicals can induce maturation and apoptosis of dendritic cells"				
	HM	MARAGOU (1996) Oral Disease, 20-6, "Alteration of integrin expression in oral squamous cell carcinomas"				
	HN	MARTIN (1997), Development 124(19):3909-3917, "Integrins mediate adhesion to agrin and modulate agrin signaling"				
	HO	MARTIN (2000) Int. J. Rad. Oncol. Biophys. 47(2):277-90 "TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target?"				
	HP	MERDAN (2002) Adv Drug Deliv Rev 54:715-758, "Prospects for cationic polymers in gene and oligonucleotide therapy against cancer"				
	HQ	MICIC "Size-dependent spectroscopy of InP quantum dots" J. Phys. Chem. B, 101(25):4904-12, 1997				
	HR	MILLER (1979) Biochem. 18:5134-5143, "Nonionic nucleic acid analogs. Synthesis and characterization of dideoxyribonucleoside methylphosphonates"				
	HS	MILLER (1980) J. Biol. Chem. 255:9659-9665, "Oligothymidylate analogues having stereoregular, alternating methylphosphonate/phosphodiester backbones"				
	HT	MOHACSI (1997) J Heart Lung Transplant 16:484-92, "Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial proliferation stimulated by PDGF or ECGF"				
	HU	MOINGEON (2002), J. Biotech. 98:189-98, "Strategies for designing vaccines eliciting Th1 responses in humans"				
	HV	NABI (2003) J Cell Biology 161(4):673-77, "Caveolae/raft-dependent endocytosis"				

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 9 of 11	ATTY. DOCKET NO. GSL01C	SERIAL NO. 10652.814
	APPLICANT Unger, et al.	
	FILING DATE August 29, 2003	GROUP 1633

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	JA						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	IB						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
IC	NIE "Probing single molecules and single nanoparticles by surface-enhanced raman scattering" Science 275(5303):1102-6, 1997
ID	NIELSEN (1991) Science 254:1497-1500, "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide"
IE	NORDE (1997) Polymeric Dispersions: Principles and Applications pp. 541-555 Kluwer Academic Publishers, Netherlands "Interaction of Proteins with Polymeric and Other Colloids"
IF	NORMAN (2000), Gene Ther. 7:1425-1430, "Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response"
IG	O'HAGAN (2001), J Virol 75(19):9037-43, "Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines"
IH	OMIDI (2003) J. of Drug Targeting 11(6):311-323 "Toxicogenomics of Non-viral Vectors for Gene Therapy: A Microarray Study of Lipofectin-and Oligofectamine-induced Gene Expression Changes in Human Epithelial Cells"
II	OTTEN (2000) Intervirology 43:227-232, "Relative potency of cellular and humoral immune responses induced in DNA vaccination"
IJ	PELKMANS (2001) Nature Cell Biology (3):473-83 "Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER"
IK	PHAM (2000) Am. J. Phys. 279(6):H2916-26, "Striated muscle-specific β 1-integrin and FAK are involved in cardiac myocyte hypertrophic response pathways"
IL	PITHA (1970) Biochim. Biophys. Acta 204:39-48, "Polyvinyluracil: the preparation and interactions with adenosine derivatives"
IM	PITHA (1970) Biopolymers 9:965-977, "Preparation and properties of poly-9-vinyl-adenosine"
IN	QUINTANAR-GUERRERO (1996) International J. of Pharmaceutics 143:133-141 "Influence of stabilizing agents and preparative variables on the formation of poly(D,L-lactic acid) nanoparticles by an emulsification-diffusion technique"
IO	REISS (1997), Breast Cancer Research & Treatment 45(1):81-95, "Transforming growth factor-beta in breast cancer, a working hypothesis"
IP	RICHARDSON (2002) Stem Cells 20:105-118 "Gene repair and transposon-mediated gene therapy"
IQ	ROUSELLE (2000) Molecular Pharmacology, 57:679-686, "New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy"
IR	RUDGINSKY (2001), Gene Ther. 4(4):347-355, "Antitumor activity of cationic lipid complexed with immunostimulatory DNA"
IS	SASAKI (2001), Nature Biotech 19:543-47, "Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases"
IT	SAZANI (2002) Nature Biotechnology, 20:1228-33, "Systemically delivered antisense oligomers upregulate gene expression in mouse tissue"
IU	SCHUELE (2000) Adv Drug Deliv Rev 44:1 19-34, "The role of CpG motifs in immunostimulation and gene therapy"
EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 10 of 11	ATTY. DOCKET NO. GSI01/C	SERIAL NO. 10/652,814
	APPLICANT Unger, et al.	
	FILING DATE August 29, 2003	GROUP 1633

U.S. PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS
	JA					

FOREIGN PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS
	JB					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	JC	SCHREDER "CdTe/CdS clusters with 'core shell' structure in colloids and films: The path of formation and thermal breakup" J. Phys. Chem. B., 104(8):1677-85, 2000.				
	JD	SENGER, Ann NY Acad Sci 760:83-100, "Osteopontin at the tumor/host interface"				
	JE	SHOJI (2004) Current Pharmaceutical Design 10(7):785-796 "Current Status of Delivery Systems to Improve Target Efficacy of Oligonucleotides"				
	JF	SIMPSON (2001) J Biol. Chem 276(21):17949-57, "Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells"				
	JG	SIMPSON (2002) Amer. J. of Path 161(3):849-857, "Inhibition of Prostate Tumor Cell Hyaluronan Synthesis Impairs Subcutaneous Growth and Vascularization in Immunocompromised Mice"				
	JH	SINGH (2002), Pharm Res. 19(6):715-28, "Recent advances in vaccine adjuvants"				
	JI	SLATON (2004) Mol. Cancer Res. 2(12):712-721 "Induction of Apoptosis by Antisense CK2 in Human Prostate Cancer Xenograft Model"				
	JJ	SPONSEL (1996) Am J. Phys (Cell Physiol. 40) 271:271-272, "Mechanisms of recovery from mechanical injury of cultured rat hepatocytes"				
	JK	STOITZNER (2001), J Invest Dermatol 118:117-125, "A closeup view of migrating langerhans cells in the skin"				
	JL	STORM (1998), Clin. Can. Res. 4:111-15, "Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system"				
	JM	TAWFIC (2001) Histo and Histopathol 16:573-82, "Protein kinase CK2 signal in neoplasia"				
	JN	TIMARES (2003), J Immunol 170:5483-5490 "Drug-inducible, dendritic cell-based genetic immunization"				
	JO	TOUSIGNANT (2000), Hu. Gene Ther. 11:2493-2513, "Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: plasmid DNA complexes in mice"				
	JP	Transdermal and Topical Drug Delivery Systems (Tapash K. Ghosh, ed. Interpharm Press, Inc. 1997)				
	JQ	TSAI (2002) J. Biol. Chem 277(35):31826-33, "Regulation of histone deacetylase by protein CK2"				
	JR	TUXHORN, J Urol. (2001) 166:2472-2483, "Reactive stroma in prostate tumor progression"				
	JS	UNGER (2002) 43:577, "Effective chemotherapeutic activity by sub50-nm nanocapsule antisense to protein kinase CK2 for eradication of in vitro tumor nests via targeted caecular-mediated endocytosis"				
	JT	UNGER (2003) AACR Proceedings, 44:1473, Abstract only: "Antisense formulation via sub50-nm nanocapsulation enhances effectiveness of problematic medicinal chemistry for tumor-specific antisense to PK CK2"				
	JU	United States Pharmacopeia, 1981 United States Pharmacopeia Dispensing Information				
	JV	VARNER (1995) Cell Ad Commun 3:367-374, "The integrin avb3: angiogenesis and apoptosis"				
	JW	VIGUSHIN (2002) Anti-cancer drugs, 13:1-13, "Histone deacetylase inhibitors in cancer treatment"				

EXAMINER *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPPE 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	DATE CONSIDERED
--	--------------------------------

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 11 of 11	ATTY. DOCKET NO. GSI01/C	SERIAL NO. 10/652,814
	APPLICANT Unger, et al.	
	FILING DATE August 29, 2003	GROUP 1633

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	KA						
	KB						
	KC						
	KD						
	KE						
	KF						
	KG						
	KH						
	KI						
	KJ						
	KK						
	KL						
	KM						
	KN						
	KO						
	KP						
	KQ						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	KR						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
KS	VIRMANI (2002), Circulation 106:2649-2651, "Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans"
KT	WANG (1995) Am. J Surg. 170(5) 502-5, "The effect of thrombospondin on oral squamous carcinoma invasion of collagen"
KU	WANG (2005) Molecular and Cellular Biochemistry 274:77-84 "Downregulation of CK2 induces apoptosis in cancer cells - A potential approach to cancer therapy"
KV	WEERATNA (2000), Intervirology 43:2128-226, "Optimization strategies for DNA vaccines".
KW	WERLING (1999), J Leuko Biol 66:50-68, "Involvement of caveolae in the uptake of respiratory syncytial virus antigen by dendritic cells"
KX	WOLFERT (1996) Gene Therapy 3:269-273 "Atomic force microscopic analysis of the influence of the molecular weight of poly(L)lysine on the size of polyelectrolyte complexes formed with DNA"
KY	WONG (2000) Chemistry of Protein Conjugation and Cross-Linking, CRC Press, Inc.
KZ	YAN (1998) J. Histochem Chem 46(1):3-10 "SPARC is expressed by ganglion cells and astrocytes in bovine retina"
KAA	
KAB	
EXAMINER	
DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	